| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Oncotelic Therapeutics, Inc. (OTLC) has 1 insider with recent SEC Form 4 filings, including 4 buys and 0 sells. OTLC is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 93.63M | $4.68M | +335.8K |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 12, 2018 | Loar Matthew M | Chief Financial Officer | Buy | 250,000 | $0.00 | - | +500.0% | |
| Dec 16, 2016 | Reynolds Donald Rogers | Director | Buy | 30,000 | $0.35 | $10,422.75 | +91.6% |